ZA200105275B - New use of melagatran. - Google Patents
New use of melagatran. Download PDFInfo
- Publication number
- ZA200105275B ZA200105275B ZA200105275A ZA200105275A ZA200105275B ZA 200105275 B ZA200105275 B ZA 200105275B ZA 200105275 A ZA200105275 A ZA 200105275A ZA 200105275 A ZA200105275 A ZA 200105275A ZA 200105275 B ZA200105275 B ZA 200105275B
- Authority
- ZA
- South Africa
- Prior art keywords
- prodrug
- pab
- melagatran
- inflammation
- solvate
- Prior art date
Links
- 229960002137 melagatran Drugs 0.000 title claims abstract description 46
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title claims abstract description 46
- 239000000651 prodrug Substances 0.000 claims abstract description 43
- 229940002612 prodrug Drugs 0.000 claims abstract description 43
- 206010061218 Inflammation Diseases 0.000 claims abstract description 35
- 230000004054 inflammatory process Effects 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 9
- 229940113118 carrageenan Drugs 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108060005987 Kallikrein Proteins 0.000 description 4
- 102000001399 Kallikrein Human genes 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9900070A SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | New use |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200105275B true ZA200105275B (en) | 2002-09-26 |
Family
ID=20414074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200105275A ZA200105275B (en) | 1999-01-13 | 2001-06-26 | New use of melagatran. |
Country Status (20)
Country | Link |
---|---|
US (3) | US6683054B1 (pt) |
EP (1) | EP1150704B1 (pt) |
JP (1) | JP2002534477A (pt) |
KR (1) | KR100701539B1 (pt) |
CN (1) | CN1170592C (pt) |
AT (1) | ATE319473T1 (pt) |
AU (1) | AU767077B2 (pt) |
BR (1) | BR0007452A (pt) |
CA (1) | CA2356611A1 (pt) |
CY (1) | CY1107465T1 (pt) |
DE (1) | DE60026491T2 (pt) |
DK (1) | DK1150704T3 (pt) |
ES (1) | ES2257282T3 (pt) |
IL (1) | IL143985A0 (pt) |
NO (1) | NO20013414D0 (pt) |
NZ (1) | NZ512713A (pt) |
PT (1) | PT1150704E (pt) |
SE (1) | SE9900070D0 (pt) |
WO (1) | WO2000041716A1 (pt) |
ZA (1) | ZA200105275B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
SE0101762D0 (sv) * | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | New use |
DE10133786A1 (de) * | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis |
SE0103590D0 (sv) * | 2001-10-26 | 2001-10-26 | Astrazeneca Ab | New Combination |
SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
SE0203349D0 (sv) * | 2002-11-12 | 2002-11-12 | Astrazeneca Ab | New use |
WO2011126903A2 (en) | 2010-03-30 | 2011-10-13 | Verseon, Inc. | Multisubstituted aromatic compounds as inhibitors of thrombin |
NZ711064A (en) | 2013-03-15 | 2019-06-28 | Verseon Corp | Pyridone-substituted pyrazolyl compounds as serine protease inhibitors |
CN110423221A (zh) | 2013-03-15 | 2019-11-08 | 维颂公司 | 作为凝血酶抑制剂的卤代吡唑 |
WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
HUE060104T2 (hu) | 2015-02-27 | 2023-01-28 | Verseon Int Corporation | Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok |
JP2021531338A (ja) | 2018-07-13 | 2021-11-18 | ヴァーセオン インターナショナル コーポレイション | トロンビン阻害薬、製剤、及びそれらの使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
US6042821A (en) * | 1995-11-21 | 2000-03-28 | Smithkline Beecham Corporation | Method of treating sepsis with chemokines |
AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
SE9600216D0 (sv) * | 1996-01-18 | 1996-01-18 | Hans Arne Hansson | Styrning av läkningsprocesser |
US5669754A (en) * | 1996-04-22 | 1997-09-23 | Advanced Dynamics Corporation Ltd. | Method and apparatus for collecting plates |
SE9601556D0 (sv) * | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
SE9603724D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
JP2002525298A (ja) | 1998-09-28 | 2002-08-13 | メルク エンド カムパニー インコーポレーテッド | トロンビン阻害剤の投与による炎症疾患の処置法 |
SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
-
1999
- 1999-01-13 SE SE9900070A patent/SE9900070D0/xx unknown
-
2000
- 2000-01-13 DE DE60026491T patent/DE60026491T2/de not_active Expired - Lifetime
- 2000-01-13 CN CNB008027935A patent/CN1170592C/zh not_active Expired - Fee Related
- 2000-01-13 IL IL14398500A patent/IL143985A0/xx unknown
- 2000-01-13 KR KR1020017008824A patent/KR100701539B1/ko not_active IP Right Cessation
- 2000-01-13 AU AU23361/00A patent/AU767077B2/en not_active Ceased
- 2000-01-13 US US09/508,762 patent/US6683054B1/en not_active Expired - Fee Related
- 2000-01-13 DK DK00902232T patent/DK1150704T3/da active
- 2000-01-13 WO PCT/SE2000/000051 patent/WO2000041716A1/en active IP Right Grant
- 2000-01-13 JP JP2000593326A patent/JP2002534477A/ja active Pending
- 2000-01-13 PT PT00902232T patent/PT1150704E/pt unknown
- 2000-01-13 CA CA002356611A patent/CA2356611A1/en not_active Abandoned
- 2000-01-13 NZ NZ512713A patent/NZ512713A/en not_active IP Right Cessation
- 2000-01-13 ES ES00902232T patent/ES2257282T3/es not_active Expired - Lifetime
- 2000-01-13 EP EP00902232A patent/EP1150704B1/en not_active Expired - Lifetime
- 2000-01-13 AT AT00902232T patent/ATE319473T1/de not_active IP Right Cessation
- 2000-01-13 BR BR0007452-7A patent/BR0007452A/pt not_active Application Discontinuation
-
2001
- 2001-06-26 ZA ZA200105275A patent/ZA200105275B/en unknown
- 2001-07-10 NO NO20013414A patent/NO20013414D0/no not_active Application Discontinuation
-
2003
- 2003-10-15 US US10/685,003 patent/US20040082518A1/en not_active Abandoned
-
2006
- 2006-06-07 CY CY20061100757T patent/CY1107465T1/el unknown
-
2007
- 2007-08-29 US US11/896,035 patent/US20080058303A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002534477A (ja) | 2002-10-15 |
ES2257282T3 (es) | 2006-08-01 |
BR0007452A (pt) | 2001-10-16 |
US6683054B1 (en) | 2004-01-27 |
EP1150704A1 (en) | 2001-11-07 |
WO2000041716A1 (en) | 2000-07-20 |
AU2336100A (en) | 2000-08-01 |
DE60026491D1 (de) | 2006-05-04 |
CY1107465T1 (el) | 2012-12-19 |
CA2356611A1 (en) | 2000-07-20 |
IL143985A0 (en) | 2002-04-21 |
ATE319473T1 (de) | 2006-03-15 |
AU767077B2 (en) | 2003-10-30 |
KR20010101492A (ko) | 2001-11-14 |
KR100701539B1 (ko) | 2007-03-30 |
NO20013414L (no) | 2001-07-10 |
NO20013414D0 (no) | 2001-07-10 |
US20080058303A1 (en) | 2008-03-06 |
US20040082518A1 (en) | 2004-04-29 |
DK1150704T3 (da) | 2006-06-12 |
EP1150704B1 (en) | 2006-03-08 |
DE60026491T2 (de) | 2006-11-02 |
NZ512713A (en) | 2004-10-29 |
CN1341028A (zh) | 2002-03-20 |
SE9900070D0 (sv) | 1999-01-13 |
CN1170592C (zh) | 2004-10-13 |
PT1150704E (pt) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080058303A1 (en) | Use of melagatran | |
EP0481675A2 (en) | Preparation of medicaments for treating asthma using (S)-alpha-fluoromethyl histidine and esters thereof | |
Lindgren et al. | Diclofenac for pain after hip surgery | |
AU2004233587A1 (en) | Use of a topical medicament comprising Riluzole | |
US20030206946A1 (en) | Methods for therapy of connective tissue disease | |
KR20010110788A (ko) | 저분자량 트롬빈 억제제 및 이의 프로드러그를 포함하는제약학적 제제 | |
DE69927497D1 (de) | Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen | |
AU2019257632A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
JP2009539996A (ja) | 腎機能障害を持つ個体における利尿改善方法 | |
KR20060004959A (ko) | 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법 | |
PT97061B (pt) | Metodo para a utilizacao de tenidap como inibidor da activacao de colagenase e da actividade de mieloperoxidase | |
KR20050100676A (ko) | 아세틸살리실산 및 안지오텐신 ⅱ 길항제와 배합된디피리다몰의 뇌졸중 예방을 위한 용도 | |
JP4306837B2 (ja) | スクラルファート含有局所投与用医薬組成物 | |
JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
KR101086040B1 (ko) | 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체 | |
MXPA01007003A (es) | Nuevo uso del melagatran | |
MXPA05005118A (es) | Una formulacion farmaceutica acuosa que comprende el inhibidor de trombina, melagatran, y el uso de la formulacion en la fabricacion de un medicamento para utilizarse a traves de adminitracion nasal en el tratamiento de tromboembolismo. | |
EP1385504B1 (en) | Method of inhibiting adhesion formation | |
JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−,鎮痛,鎮静剤 | |
JP2001163783A (ja) | 皮膚疾患治療用外用剤 | |
WO2022106851A1 (en) | Mebendazole for use in the treatment of autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease | |
JPS61172820A (ja) | カルシウム拮抗剤 | |
MXPA01007833A (es) | Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria. | |
US20040157772A1 (en) | Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis | |
JPH09118619A (ja) | 放射線障害予防・治療剤 |